Startup Ripple, which sells ad space on flat panel TVs placed in retail outlets, grabs $10 million in funds.
|
FDA mandates tough new warnings for anemia drugs Aranesp and Epogen.
|
Court of Appeal Upholds Proposition 71.
|
Cabilly patent overturned; FDA wants new Xolair warning; Avastin sales threatened.
|
Shire looks to beat generic competition for Adderall.
|
International study illuminates a genetic predisposition to autism.
|
Report says that new legislation would bring big savings.
|
Protein discovery could be the key to an HIV vaccine.
|
Breakthrough could lead to personalized treatments for deadly illness in 15 to 20 years.
|
Large-scale trial hopes to produce an immune response.
|
Neulasta and Neupogen may increase leukemia risk, but investors are doubtful.
|
Scientists look to find out why so many drugs fail in phase three.
|
Topical gel intended to prevent HIV transmission actually increases it.
|
FDA panel says rival device ineffective, but depression treatment maker not out of woods yet.
|
Revenues are up, but Aranesp disappoints.
|
The Red Herring Minute with Marisa Taylor: YouTube Censored; Google Eyes India and AdScape; Microsoft's Gears of War; Apple's iPhone Gaming
|
Earnings for drug maker’s fourth quarter are flat.
|
3 contracts granted for vaccine stockpile.
|
Tanox shareholders approve the acquisition by Genentech.
|
Mutations in gene might contribute to late-onset Alzheimer’s disease.
|
Page
1
of
3
|